Market Scenario
The global point of care molecular diagnostic market was valued at USD 1.62 billion in 2018 and t is expected to grow at a healthy CAGR of 6.4% during 2019-2026.
Point of care testing molecular diagnostic is medical diagnostic testing at or near the point of care. Point of care molecular diagnostic test is used to detect infectious disease, genetic diseases and others. During last decades there is a significant increase in the prevalence of chronic diseases which has led to increase in the patient inflow. Point of care test is useful in providing the immediate results to the patient. According to the research conducted by the Johns Hopkins University, in 2012, 1.4 million people were suffering from chronic hepatitis B.
The global point of care molecular diagnostic market is majorly driven by increasing prevalence of the infectious diseases, hematological diseases, cancer, and others. Increasing government support and increasing healthcare awareness among the people have fuelled the growth of the market. Moreover, growth in biomarker identification and development in molecular diagnostic techniques have supported the growth of the market.
Though there are good opportunities for the growth of the market. To introduce the test and devices into the market the product has to meet the strict government regulations for devices or test. This stringent government regulations and poor reimbursement policies may hinder the growth of the market during the forecasted period.
The market is majorly grabbed by developed region, thus the manufacturers can grab the opportunity of the development of the market in developing region.
Segmentation
The global point of care molecular diagnostic market is segmented on the basis of techniques, applications and end users.
On the basis of techniques, the point of care testing molecular diagnostic market is segmented into polymerase chain reaction (PCR), hybridization, DNA diagnostics, microarrays, and others.
On the basis of application, the point of care testing molecular diagnostic market is segmented into infectious diseases, hematology, endocrinology, oncology, and other. Infectious diseases are further segmented into hepatitis B, hepatitis C, HIV, TB, MRSA, and others.
On the basis of end users, the point of care testing molecular diagnostic market is segmented into professional diagnostics laboratories, molecular diagnostics laboratories, and others.
Regional Analysis
On regional basis the global point of care molecular diagnostic market is segmented into America, Europe, Asia Pacific and The Middle East & Africa. America commands for the largest share in the global point of care molecular diagnostic market owing to the huge patient population well developed economy and high healthcare expenditure. According to the National Cancer Institute, in 2016, 1.6 million Americans were suffering from cancer.
Europe commands the second largest share in the market. Strong government support for research and increasing prevalence of chronic diseases has driven the growth of Europe market. Asia Pacific has the fastest growing market due to the presence of huge opportunity for the development of the market and huge population base in this region.
On the other hand, the Middle East & Africa holds the least share in the point of care testing molecular diagnostic market due to limited development in healthcare technology and poor economy in Africa region.
Key Players
The key players in the point of care testing molecular diagnostic market are: F. Hoffmann-La Roche Ltd (Switzerland), Alere (U.S.), Thermo Fisher Scientific (U.S.), Abbott Laboratories (U.S.), Siemens Healthcare GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Danaher (U.S.), QIAGEN (Germany), Johnson & Johnson Services, Inc. (U.S.), and Ortho Clinical Diagnostics (U.S.)
Segmentation
Polymerase Chain Reaction (PCR)
Hybridization
DNA Diagnostics
Microarrays
Others
Infectious Diseases
Hepatitis B
Hepatitis C
HIV
TB
MRSA
Others
Hematology
Endocrinology
Oncology
Other
Professional Diagnostics Laboratories
Molecular Diagnostics Laboratories
Others
Global Point Of Care Molecular Diagnostic Market
F. Hoffmann-La Roche Ltd
Alere
Thermo Fisher Scientific
Abbott Laboratories
Siemens Healthcare GmbH
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
Danaher
QIAGEN
Johnson & Johnson Services, Inc.
Ortho Clinical Diagnostics (U.S.)
1. Introduction
1.1. Market Definition
1.2. Market Scope
2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions
3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Value Chain Analysis
3.3. Key Market Trend Analysis
3.3.1. Market Drivers
3.3.2. Market Restraint/Challenges
3.3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Market Share Analysis, 2018
3.6. Regulatory Framework
3.7. Consumer Behavior Analysis
4. Techniques Overview
4.1. Introduction
4.2. Market Size & Forecast, 2016 to 2026
4.2.1. Polymerase Chain Reaction (PCR)
4.2.2. Hybridization
4.2.3. DNA Diagnostics
4.2.4. Microarrays
4.2.5. Others
5. Application Overview
5.1. Introduction
5.2. Market Size & Forecast, 2016 to 2026
5.2.1. Infectious Diseases
5.2.1.1. Hepatitis B
5.2.1.2. Hepatitis C
5.2.1.3. HIV
5.2.1.4. TB
5.2.1.5. MRSA
5.2.1.6. Others
5.2.2. Hematology
5.2.3. Endocrinology
5.2.4. Oncology
5.2.5. Other
6. End Users Overview
6.1. Introduction
6.2. Market Size & Forecast, 2016 to 2026
6.2.1. Professional Diagnostics Laboratories
6.2.2. Molecular Diagnostics Laboratories
6.2.3. Others
7. Regional Overview
7.1. Introduction
7.2. Market Size & Forecast, 2016 to 2026
7.2.1. Americas
7.2.1.1. North America
7.2.1.1.1. U.S.
7.2.1.1.2. Canada
7.2.1.2. South America
7.2.2. Europe
7.2.2.1. Western Europe
7.2.2.1.1. Germany
7.2.2.1.2. France
7.2.2.1.3. U.K.
7.2.2.1.4. Italy
7.2.2.1.5. Spain
7.2.2.1.6. Rest Of Western Europe
7.2.2.2. Eastern Europe
7.2.3. Asia Pacific
7.2.3.1. Japan
7.2.3.2. China
7.2.3.3. India
7.2.3.4. Australia
7.2.3.5. Rest of Asia Pacific
7.2.4. The Middle East & Africa
7.2.4.1. The Middle East
7.2.4.1.1. UAE
7.2.4.1.2. Saudi Arabia
7.2.4.1.3. Qatar
7.2.4.1.4. Rest of the Middle East
7.2.4.2. Africa
8. Manufacturer/ Vendor Profile
8.1. The following attributes will be considered while profiling key manufacturers in this industry:
8.1.1. Company Overview
8.1.2. Financial Synopsis
8.1.3. Recent Developments
8.1.4. R&D Investments (if any)
8.1.5. Strategy Overview (Analyst Perspective)
8.1.6. Product Portfolio
8.2. Companies Profiled
8.2.1. F. Hoffmann-La Roche Ltd
8.2.2. Danaher
8.2.3. Abbott Laboratories
8.2.4. Siemens Healthcare GmbH
8.2.5. QIAGEN
8.2.6. Johnson & Johnson Services, Inc.
8.2.7. Thermo Fisher Scientific
8.2.8. Bio-Rad Laboratories, Inc.
8.2.9. Becton, Dickinson and Company
8.2.10. Alere
8.2.11. Ortho Clinical Diagnostics
© 2019 Data N Analysis. All Rights Reserved | Design by Data N Analysis